Literature DB >> 17166407

Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes.

X F Yang1, D Mirkovic, S Zhang, Q E Zhang, Y Yan, Z Xiong, F Yang, I H Chen, L Li, H Wang.   

Abstract

In order to improve the processing efficiency of T cell tumor antigen epitopes, this bioinformatic study compares proteolytic sites in the generation of 47 experimentally identified HLA-A2.1-restricted immunodominant tumor antigen epitopes to those of 52 documented HLA-A2.1-restricted immunodominant viral antigen epitopes. Our results show that the amino acid frequencies in the C-terminal cleavage sites of the tumor antigen epitopes, as well as several positions within the 10 amino acid (aa) flanking regions, are significantly different from those of the viral antigen epitopes. In the 9 amino acid epitope region, frequencies differed somewhat in the secondary-anchored amino acid residues on E3 (the third aa of the epitope), E4, E6, E7 and E8; however, frequencies in the primary-anchored positions, on E2 and E9, for binding in the HLA-A2.1 groove, remained almost identical. The most frequently occurring amino acid pairs in both N-terminal and C-terminal cleavage sites in the generation of tumor antigen epitopes were different from those of the viral antigen epitopes. Our findings demonstrate for the first time that these two groups of epitopes may be cleaved by distinct sets of proteasomes and peptidases or similar enzymes with lower efficiencies for tumor epitopes. In the future, in order to more effectively generate tumor antigen epitopes, targeted activation of the immunoproteasomes and peptidases that mediate the cleavage of viral epitopes could be achieved, thus enhancing our potential for antigen-specific tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17166407      PMCID: PMC2888035          DOI: 10.1177/039463200601900415

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  67 in total

Review 1.  Differential processing of class-I-restricted epitopes by the standard proteasome and the immunoproteasome.

Authors:  B J Van den Eynde; S Morel
Journal:  Curr Opin Immunol       Date:  2001-04       Impact factor: 7.486

Review 2.  Identification of cancer antigens: impact on development of cancer immunotherapies.

Authors:  S A Rosenberg
Journal:  Cancer J       Date:  2000-05       Impact factor: 3.360

Review 3.  A listing of human tumor antigens recognized by T cells.

Authors:  N Renkvist; C Castelli; P F Robbins; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  2001-03       Impact factor: 6.968

4.  Human memory CTL response specific for influenza A virus is broad and multispecific.

Authors:  C Gianfrani; C Oseroff; J Sidney; R W Chesnut; A Sette
Journal:  Hum Immunol       Date:  2000-05       Impact factor: 2.850

Review 5.  Cancer vaccine: identification of human tumor antigens by SEREX.

Authors:  Y T Chen
Journal:  Cancer J       Date:  2000-05       Impact factor: 3.360

6.  Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.

Authors:  B Seliger; U Wollscheid; F Momburg; T Blankenstein; C Huber
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

7.  Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.

Authors:  C J Wu; X F Yang; S McLaughlin; D Neuberg; C Canning; B Stein; E P Alyea; R J Soiffer; G Dranoff; J Ritz
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

8.  Structural basis for the activation of 20S proteasomes by 11S regulators.

Authors:  F G Whitby; E I Masters; L Kramer; J R Knowlton; Y Yao; C C Wang; C P Hill
Journal:  Nature       Date:  2000-11-02       Impact factor: 49.962

Review 9.  Homeostatic T cell proliferation: how far can T cells be activated to self-ligands?

Authors:  C D Surh; J Sprent
Journal:  J Exp Med       Date:  2000-08-21       Impact factor: 14.307

Review 10.  Challenges to the development of antigen-specific breast cancer vaccines.

Authors:  M J Scanlan; D Jäger
Journal:  Breast Cancer Res       Date:  2001-01-11       Impact factor: 6.466

View more
  16 in total

1.  Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera.

Authors:  Zeyu Xiong; Yan Yan; Enli Liu; Richard T Silver; Srdan Verstovsek; Fan Yang; Hong Wang; Josef Prchal; Xiao-Feng Yang
Journal:  Clin Immunol       Date:  2006-11-17       Impact factor: 3.969

Review 2.  Vascular Endothelial Cells and Innate Immunity.

Authors:  Ying Shao; Jason Saredy; William Y Yang; Yu Sun; Yifan Lu; Fatma Saaoud; Charles Drummer; Candice Johnson; Keman Xu; Xiaohua Jiang; Hong Wang; Xiaofeng Yang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-05-27       Impact factor: 8.311

Review 3.  Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics.

Authors:  Michael Jan; Shu Meng; Natalie C Chen; Jietang Mai; Hong Wang; Xiao-Feng Yang
Journal:  J Biomed Biotechnol       Date:  2010-04-15

4.  Metabolic Diseases Downregulate the Majority of Histone Modification Enzymes, Making a Few Upregulated Enzymes Novel Therapeutic Targets--"Sand Out and Gold Stays".

Authors:  Ying Shao; Valeria Chernaya; Candice Johnson; William Y Yang; Ramon Cueto; Xiaojin Sha; Yi Zhang; Xuebin Qin; Jianxin Sun; Eric T Choi; Hong Wang; Xiao-feng Yang
Journal:  J Cardiovasc Transl Res       Date:  2016-01-08       Impact factor: 4.132

5.  Lysophospholipids induce innate immune transdifferentiation of endothelial cells, resulting in prolonged endothelial activation.

Authors:  Xinyuan Li; Luqiao Wang; Pu Fang; Yu Sun; Xiaohua Jiang; Hong Wang; Xiao-Feng Yang
Journal:  J Biol Chem       Date:  2018-05-16       Impact factor: 5.157

6.  The Role of Immunogenicity in Cardiovascular Disease.

Authors:  Michael Jan; Anthony T Virtue; Meghanaben Pansuria; Jingshan Liu; Xinyu Xiong; Pu Fang; Shu Meng; Hong Wang; Xiao-Feng Yang
Journal:  World Heart J       Date:  2011-01-01

7.  Caspase-1 recognizes extended cleavage sites in its natural substrates.

Authors:  Jerry Shen; Ying Yin; Jietang Mai; Xinyu Xiong; Meghana Pansuria; Jingshan Liu; Erin Maley; Najam Us Saqib; Hong Wang; Xiao-Feng Yang
Journal:  Atherosclerosis       Date:  2009-12-22       Impact factor: 5.162

8.  A novel unconventional antigen MPD5 elicits anti-tumor humoral immune responses in a subset of patients with polycythemia vera.

Authors:  Z Xiong; E Liu; Y Yan; R T Silver; F Yang; I H Chen; I Hodge; S Verstovsek; F J Segura; H Wang; J Prchal; X F Yang
Journal:  Int J Immunopathol Pharmacol       Date:  2007 Apr-Jun       Impact factor: 3.219

9.  HLA-A2.1-restricted T cells react to SEREX-defined tumor antigen CML66L and are suppressed by CD4+CD25+ regulatory T cells.

Authors:  Y Yan; Y Chen; F Yang; I H Chen; Z Xiong; J Wang; L B Lachman; H Wang; X-F Yang
Journal:  Int J Immunopathol Pharmacol       Date:  2007 Jan-Mar       Impact factor: 3.219

10.  Structural evidence of anti-atherogenic microRNAs.

Authors:  Anthony Virtue; Jietang Mai; Ying Yin; Shu Meng; Tran Tran; Xiaohua Jiang; Hong Wang; Xiao-Feng Yang
Journal:  Front Biosci (Landmark Ed)       Date:  2011-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.